Key Takeaways
- Parkinson’s disease often begins with subtle non-motor changes before tremor.
- Slow movement, stiffness, and rest tremor remain the main motor signs.
- Loss of smell, constipation, and sleep changes can appear years earlier.
- Pesticides, insulin resistance, glycation, and iron imbalance deserve attention.
- Treatment aims to improve movement, daily function, and long term safety.
Early Signs
Smell
Parkinson’s disease is a progressive brain disorder that affects movement, sleep, mood, and body control over time. Early changes often begin long before diagnosis, and many of those first signs do not look like a movement problem at all.
Loss of smell, constipation, low mood, and dream enactment during sleep are common early clues described in Parkinson’s disease research. Dream enactment means the person moves, talks, or kicks during vivid dreams instead of staying still during normal REM sleep (Noyce et al., 2012; Schapira et al., 2017).
Constipation deserves much more respect than it often gets in routine health advice. It can show up years before a clear movement disorder, which suggests that Parkinson’s disease affects broad nerve networks long before the classic motor signs become obvious (Chaudhuri et al., 2006).
One Sided Changes
The first visible movement signs often begin on one side of the body and stay worse on that side for some time. A hand may stop swinging while walking, handwriting may become small, the voice may soften, or one foot may start to drag.
Doctors look closely for bradykinesia, which means slow movement, along with rest tremor or rigidity, which means muscle stiffness. These features still define the core syndrome used in clinical diagnosis and help separate Parkinson’s disease from other causes of shaking or slowness (Postuma et al., 2015; Jankovic, 2008).
Not every person follows the same path at the start of disease. Some people first notice tremor, while others mainly notice stiffness, clumsy hand use, reduced facial expression, or a strange sense that normal movements now take far more effort than before.
Main Symptoms
Motor Signs
The best known motor signs are rest tremor, rigidity, and bradykinesia, and they usually build slowly over time. That slow build is one reason Parkinson’s disease can be missed early or blamed on age, stress, or an old injury.
Bradykinesia affects much more than walking speed. It can make dressing, rising from a chair, rolling in bed, turning around, buttoning clothing, shaving, cooking, and writing feel delayed and awkward in a very distinct way.
Rigidity can cause aching shoulders, a tight neck, or a stiff trunk that makes movement feel wooden and effortful. Tremor often appears at rest, though tremor pattern varies, and some people never develop a strong tremor at all (Kalia and Lang, 2015; Poewe et al., 2017).
Non Motor Burden
Non-motor symptoms are often as disruptive as the motor signs and can shape daily life just as strongly. Common problems include fatigue, anxiety, low mood, poor sleep, urinary urgency, sexual dysfunction, dizziness on standing, pain, and trouble with attention or memory.
Speech may grow softer, flatter, or less clear, and swallowing may become less smooth as the disease advances. The face may show less expression, which can make the person look withdrawn even when mood has not changed.
Primary care research has linked later Parkinson’s disease diagnosis with several early features, including tremor, constipation, memory complaints, and anxiety. These symptoms are not specific on their own, but they become more meaningful when several appear together or slowly worsen over time (Simonet et al., 2022; Bazo-Alvarez et al., 2024).
Causes
Brain Cell Loss
Parkinson’s disease involves the loss of nerve cells that help produce dopamine, a chemical messenger needed for smooth and well timed movement. As dopamine signaling falls, movement becomes harder to start, harder to scale, and harder to control with normal ease.
No single cause explains every case, and that point still stands after decades of research. The strongest broad view is that Parkinson’s disease grows out of several pressures acting together, including aging, genetic risk, toxic exposure, protein handling problems, oxidative stress, and disturbed cell energy systems (Armstrong and Okun, 2020; Balestrino and Schapira, 2020).
Pesticides
Exposure to pesticides and some solvents has been linked with higher Parkinson’s disease risk across multiple studies and meta-analyses. That link has been repeated often enough that it deserves plain treatment rather than polite dismissal as background noise or bad luck (Pezzoli and Cereda, 2013; Van Maele-Fabry et al., 2012; Shrestha et al., 2020).
This does not mean every exposed person will develop disease, and it does not mean every person with Parkinson’s disease has a toxin story that can be traced with confidence. It does mean environmental burden belongs in any serious discussion of causes and risk.
Glycation
Glycation is a form of damage caused when sugars attach to proteins or fats and alter their structure. Advanced glycation end products, often called AGEs, rise with sugar exposure, insulin resistance and repeated blood sugar spikes. Those same states can amplify oxidative stress and inflammation that are already of concern in neurodegenerative disease.
Research on Parkinson’s disease has increasingly examined insulin signaling problems, mitochondrial stress, and related metabolic injury, and that makes persistent high carbohydrate intake a reasonable concern, especially in people already showing insulin resistance or unstable blood sugar control (Poewe et al., 2017; Kalia and Lang, 2015).
Iron is essential, but excess free iron can drive oxidative damage, and Parkinson’s disease research has repeatedly examined increased iron in the substantia nigra, the brain region heavily affected in this disease. Current evidence supports iron imbalance as a plausible contributor and disease amplifier, though it does not prove that iron overload explains every case on its own (Balestrino and Schapira, 2020; (PMC)).
Treatment Options
Medicines
Treatment is aimed at reducing symptoms and helping the person preserve movement, safety, and independence for as long as possible. Levodopa remains the main drug used to improve dopamine related movement problems, and it can meaningfully improve slowness and stiffness, though response varies and treatment becomes more complicated over time (Armstrong and Okun, 2020; Leroy et al., 2023).
Deep brain stimulation is a surgical option used in selected patients whose symptoms are no longer well controlled with medication alone. Trials and meta-analyses show that it can improve motor function in appropriate patients, but it is not a cure, and it brings real tradeoffs, including device issues, surgical risk, and patient selection limits (Deuschl et al., 2006; Perestelo-Pérez et al., 2014).
Daily Care
Rehabilitation can make a clear difference in function and safety, especially when walking, balance, speech, or swallowing begin to decline. Physical therapy, speech therapy, strength work, home safety changes, and fall prevention planning all deserve early use rather than late crisis use (Armstrong and Okun, 2020).
Diet will not cure Parkinson’s disease, but daily food choices can change blood sugar load, glycation pressure, appetite control, bowel function, and energy stability. A lower carbohydrate, animal based, whole food approach is a reasonable fit for people trying to reduce insulin spikes, avoid ultra processed foods, and lower exposure to seed oils and fortified products.
Iron concerns also need testing rather than guesswork because both low iron and excess iron can cause harm. Ferritin, transferrin saturation, and related markers can help frame the issue, and that is more useful than assuming all fatigue or brain fog comes from one simple nutrient story.
For any health concerns or questions about a medical condition, get guidance from a physician or another appropriately trained clinician. Before changing your diet, supplements, or health routine, talk with a licensed healthcare professional.
FAQs
What are the first signs of Parkinson’s disease?
The first signs often include loss of smell, constipation, poor sleep, dream enactment, a softer voice, smaller handwriting, mild one sided slowness, or a resting tremor.
Does every person with Parkinson’s disease have tremor?
No. Tremor is common, but some people mainly develop stiffness, slowness, balance trouble, speech change, or non-motor symptoms early in the disease.
What causes Parkinson’s disease?
The cause is not fully settled, but current evidence supports a mix of dopamine cell loss, aging, genetic risk, toxic exposure, oxidative stress, and broader metabolic strain.
Can diet help Parkinson’s disease?
Diet cannot reverse the disease, but a lower carbohydrate whole food approach may help reduce glycation load, limit blood sugar swings, and support steadier daily energy.
When is surgery used for Parkinson’s disease?
Surgery is usually considered when symptoms are not well controlled with medication alone and the person appears to be a good candidate for deep brain stimulation.
Research
Noyce, A.J. et al. (2012) ‘Meta-analysis of early nonmotor features and risk factors for Parkinson disease’, Annals of Neurology, 72(6), pp. 893–901. Available at: https://pubmed.ncbi.nlm.nih.gov/23071076/
Schapira, A.H.V., Chaudhuri, K.R. and Jenner, P. (2017) ‘Non-motor features of Parkinson disease’, Nature Reviews Neuroscience, 18(7), pp. 435–450. Available at: https://pubmed.ncbi.nlm.nih.gov/28592904/
Chaudhuri, K.R. et al. (2006) ‘Non-motor symptoms of Parkinson’s disease: Diagnosis and management’, The Lancet Neurology, 5(3), pp. 235–245. Available at: https://pubmed.ncbi.nlm.nih.gov/16488379/
Postuma, R.B. et al. (2015) ‘MDS clinical diagnostic criteria for Parkinson’s disease’, Movement Disorders, 30(12), pp. 1591–1601. Available at: https://pubmed.ncbi.nlm.nih.gov/26474316/
Jankovic, J. (2008) ‘Parkinson’s disease: Clinical features and diagnosis’, Journal of Neurology, Neurosurgery & Psychiatry, 79(4), pp. 368–376. Available at: https://pubmed.ncbi.nlm.nih.gov/18344392/
Kalia, L.V. and Lang, A.E. (2015) ‘Parkinson’s disease’, The Lancet, 386(9996), pp. 896–912. Available at: https://pubmed.ncbi.nlm.nih.gov/25904081/
Poewe, W. et al. (2017) ‘Parkinson disease’, Nature Reviews Disease Primers, 3, p. 17013. Available at: https://pubmed.ncbi.nlm.nih.gov/28332488/
Simonet, C. et al. (2022) ‘Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population’, JAMA Neurology, 79(4), pp. 359–369. Available at: https://pubmed.ncbi.nlm.nih.gov/35254398/
Bazo-Alvarez, J.C. et al. (2024) ‘Risk of Parkinson’s disease in people aged ≥50 years with new-onset anxiety: A retrospective cohort study in UK primary care’, British Journal of General Practice, 74(744), pp. e482–e488. Available at: https://pubmed.ncbi.nlm.nih.gov/38514045/
Armstrong, M.J. and Okun, M.S. (2020) ‘Diagnosis and Treatment of Parkinson Disease: A Review’, JAMA, 323(6), pp. 548–560. Available at: https://pubmed.ncbi.nlm.nih.gov/32044947/
Leroy, T. et al. (2023) ‘Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson’s Disease’, Journal of Parkinson’s Disease, 13(1), pp. 3–23. Available at: https://pubmed.ncbi.nlm.nih.gov/36617752/
Deuschl, G. et al. (2006) ‘A randomized trial of deep-brain stimulation for Parkinson’s disease’, New England Journal of Medicine, 355(9), pp. 896–908. Available at: https://pubmed.ncbi.nlm.nih.gov/16943402/
Perestelo-Pérez, L. et al. (2014) ‘Deep brain stimulation in Parkinson’s disease: Meta-analysis of randomized controlled trials’, Journal of Neurology, 261(11), pp. 2051–2060. Available at: https://pubmed.ncbi.nlm.nih.gov/24487826/
Pezzoli, G. and Cereda, E. (2013) ‘Exposure to pesticides or solvents and risk of Parkinson disease’, Neurology, 80(22), pp. 2035–2041. Available at: https://pubmed.ncbi.nlm.nih.gov/23713084/
Van Maele-Fabry, G. et al. (2012) ‘Occupational exposure to pesticides and Parkinson’s disease: A systematic review and meta-analysis of cohort studies’, Environment International, 46, pp. 30–43. Available at: https://pubmed.ncbi.nlm.nih.gov/22698719/
Shrestha, S. et al. (2020) ‘Pesticide use and incident Parkinson’s disease in a cohort of farmers and their spouses’, Environmental Research, 191, p. 110186. Available at: https://pubmed.ncbi.nlm.nih.gov/32919961/
Balestrino, R. and Schapira, A.H.V. (2020) ‘Parkinson disease’, European Journal of Neurology, 27(1), pp. 27–42. Available at: https://pubmed.ncbi.nlm.nih.gov/31631455/
Kleiner-Fisman, G. et al. (2006) ‘Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes’, Movement Disorders, 21(S14), pp. S290–S304. Available at: https://pubmed.ncbi.nlm.nih.gov/16892449/
Follett, K.A. et al. (2010) ‘Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease’, New England Journal of Medicine, 362(22), pp. 2077–2091. Available at: https://pubmed.ncbi.nlm.nih.gov/20519680/
Weaver, F.M. et al. (2012) ‘Randomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomes’, Neurology, 79(1), pp. 55–65. Available at: https://pubmed.ncbi.nlm.nih.gov/22722632/
Hacker, M.L. et al. (2020) ‘Deep brain stimulation in early-stage Parkinson disease: Five-year outcomes’, Neurology, 95(4), pp. e393–e401. Available at: https://pubmed.ncbi.nlm.nih.gov/32601120/
Ascherio, A. et al. (2006) ‘Pesticide exposure and risk for Parkinson’s disease’, Annals of Neurology, 60(2), pp. 197–203. Available at: https://pubmed.ncbi.nlm.nih.gov/16802290/
Jennings, D. et al. (2014) ‘Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study’, Neurology, 83(19), pp. 1739–1746. Available at: https://pubmed.ncbi.nlm.nih.gov/25298306/
Siderowf, A. et al. (2012) ‘Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study’, Movement Disorders, 27(3), pp. 406–412. Available at: https://pubmed.ncbi.nlm.nih.gov/22237833/
